Calculation of molecular features with apparent impact on both activity of mutagens and activity of anticancer agents

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 7, 2012, Pages 807-817

  Toropov, Andrey A ^a   Toropova, Alla P ^a   Benfenati, Emilio ^a   Gini, Giuseppina ^b   Leszczynska, Danuta ^c   Leszczynski, Jerzy ^d  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b POLITECNICO DI MILANO   (Italy)

^c Jackson State University   (United States)

^d JACKSON STATE UNIVERSITY   (United States)

Author keywords

Anticancer activity; CORAL software; Mutagenicity; QSAR; SMILES; Validation

Indexed keywords

1,4 DIHYDRO 4 OXO 1 (2 THIAZOLYL) 1,8 NAPHTHYRIDINE; ANTINEOPLASTIC AGENT; MUTAGENIC AGENT; NAPHTHYRIDINE DERIVATIVE; NITROGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; COMPUTER PROGRAM; MOUSE; MUTAGENICITY; NONHUMAN;

EID: 84866352647     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012802650255     Document Type: Article

References (61)

1. Weininger, D.; SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules. J. Chem. Inf. Comput. Sci., 1988, 28, 31-36.
2. Weininger, D.; Weininger, A.; Weininger, J.L. SMILES. 2. Algorithm for generation of unique SMILES notation J. Chem. Inf. Compu. Sci., 1989, 29, 97-101.
3. Weininger, D. Smiles. 3. Depict. Graphical depiction of chemical structures J. Chem. Inf. Comput. Sci., 1990, 30 (3), 237-243.
4. Advanced Chemistry Development, Inc., Toronto, Canada, ACD/Chemsketch software, A complete software package for drawing chemical structures, http://www.acdlabs.com/products/draw_nom/draw/chemsketch/ (accessed February 7, 2012)
5. García, J.; Duchowicz, P.R.; Rozas, M.F.; Caram, J.A., Mirífico, M.V.; Fernández, F.M., Castro, E.A. A comparative QSAR on 1,2,5-thiadiazolidin-3-one 1,1-dioxide compounds as selective inhibitors of human serine proteinases. J. Mol. Graph. Model., 2011, 31, 10-19.
6. Mullen, L.M.A.; Duchowicz, P.R.; Castro, E.A. QSAR treatment on a new class of triphenylmethyl-containing compounds as potent anticancer agents. Chemometr. Intell. Lab., 2011, 107 (2), 269-275.
7. Mercader, A.G.; Duchowicz, P.R.; Fernández, F.M.; Castro, E.A. Replacement method and enhanced replacement method versus the genetic algorithm approach for the selection of molecular descriptors in QSPR/QSAR theories. J. Chem. Inf. Model., 2010, 50 (9), 1542-1548.
8. Toropov, A.A.; Toropova, A.P.; Martyanov, S.E.; Benfenati, E.; Gini, G.; Leszczynska, D.; Leszczynski, J. Comparison of SMILES and molecular graphs as the representation of the molecular structure for QSAR analysis for mutagenic potential of polyaromatic amines. Chemometr. Intell. Lab., 2011, 109 (1), 94-100.
9. Toropova, A.P.; Toropov, A.A.; Benfenati, E.; Gini, G.; Leszczynska, D.; Leszczynski, J. CORAL: Quantitative structureactivity relationship models for estimating toxicity of organic compounds in rats. J. Comput. Chem., 2011, 32 (12), 2727-2733.
10. Benfenati, E.; Toropov, A.A.; Toropova, A.P.; Manganaro, A.; Gonella Diaza, R. CORAL software: QSAR for anticancer agents. Chem. Biol. Drug Des., 2011, 77 (6), 471-476.
11. Toropov, A.A.; Toropova, A.P.; Lombardo, A.; Roncaglioni, A.; Benfenati, E.; Gini, G. CORAL: Building up the model for bioconcentration factor and defining it's applicability domain. Eur. J. Med. Chem., 2011, 46 (4), 1400-1403.
12. Toropova, A.P.; Toropov, A.A.; Diaza, R.G.; Benfenati, E.; Gini, G. Analysis of the co-evolutions of correlations as a tool for QSAR-modeling of carcinogenicity: An unexpected good prediction based on a model that seems untrustworthy. Cent. Eur. J. Chem., 2011, 9 (1), 165-174.
13. Toropova, A.P.; Toropov, A.A.; Benfenati, E.; Gini, G. Coevolutions of correlations for QSAR of toxicity of organometallic and inorganic substances: An unexpected good prediction based on a model that seems untrustworthy Chemometr. Intell. Lab., 2011, 105 (2), 215-219.
14. Toropova, A.P.; Toropov, A.A.; Benfenati, E.; Gini, G.; Leszczynska, D.; Leszczynski, J. CORAL: QSPR models for solubility of [C60 and [C70 fullerene derivatives. Mol. Divers., 2011, 15 (1), 249-256.
15. Toropova, A.P.; Toropov, A.A.; Benfenati, E.; Gini, G. QSAR modelling toxicity toward rats of inorganic substances by means of CORAL Cent. Eur. J. Chem., 2011, 9 (1), 75-85.
16. Toropov, A.A.; Toropova, A.P.; Benfenati, E. SMILES-based optimal descriptors: QSAR modeling of carcinogenicity by balance of correlations with ideal slopes. Eur. J. Med. Chem., 2011, 45 (9), 3581-3587.
17. Toropova, A.P.; Toropov, A.A.; Lombardo, A.; Roncaglioni, A.; Benfenati, E.; Gini, G. A new bioconcentration factor model based on SMILES and indices of presence of atoms. Eur. J. Med. Chem., 2010, 45 (9), 4399-4402.
18. Toropova, A.P.; Toropov, A.A.; Benfenati, E.; Leszczynska, D.; Leszczynski, J. QSAR modeling of measured binding affinity for fullerene-based HIV-1 PR inhibitors by CORAL. J. Math. Chem., 2010, 48 (4), 959-987.
19. Benigni, R.; Bossa, C. Alternative strategies for carcinogenicity assessment: An efficient and simplified approach based on in vitro mutagenicity and cell transformation assays. Mutagenesis, 2011, 26 (3), 455-460.
20. Benigni, R.; Bossa, C. Mechanisms of chemical carcinogenicity and mutagenicity: A review with implications for predictive toxicology. Chem. Rev., 2011, 111 (4), 2507-2536.
21. Benigni, R.; Bossa, C.; Tcheremenskaia, O.; Giuliani, A. Alternatives to the carcinogenicity bioassay: In silico methods, and the in vitro and in vivo mutagenicity assays. Expert Opin. Drug Metabol. Toxicol., 2010, 6 (7), 809-819.
22. Combes, R.; Grindon, C.; Cronin, M.T.D.; Roberts, D.W.; Garrod, J.F. Integrated decision-tree testing strategies for mutagenicity and carcinogenicity with respect to the requirements of the EU REACH legislation. ATLA Altern. Lab. Anim., 2008, 36 (SUPPL. 1), 43-63.
23. Combes, R.; Grindon, C.; Cronin, M.T.D.; Roberts, D.W.; Garrod, J. Proposed integrated decision-tree testing strategies for mutagenicity and carcinogenicity in relation to the EU REACH legislation. ATLA Altern. Lab. Anim., 2007, 35 (2), 267-287.
24. Helma, C. Lazy structure-activity relationships (lazar) for the prediction of rodent carcinogenicity and Salmonella mutagenicity. Mol. Divers., 2006, 10 (2), 147-158.
25. Benigni, R. Computational prediction of drug toxicity: The case of mutagenicity and carcinogenicity Drug Discov. Today: Technol., 2004, 1 (4),457-463.
26. Benigni, R.; Passerini, L.; Rodomonte, A. Structure-Activity Relationships for the Mutagenicity and Carcinogenicity of Simple and α-β Unsaturated Aldehydes. Environ. Mol. Mutagen., 2003, 42 (3), 136-143.
27. Patlewicz, G.; Rodford, R.; Walker, J.D. Quantitative structureactivity relationships for predicting mutagenicity and carcinogenicity. Environ. Toxicol. Chem., 2003, 22 (8), 1885-1893.
28. Novak, M.; Rajagopal, S. Correlations of nitrenium ion selectivities with quantitative mutagenicity and carcinogenicity of the corresponding amines. Chem. Res. Toxicol., 2002, 15(12), 1495-1503.
29. Rosenkranz, H.S.; Karol, M.H. Chemical carcinogenicity: Can it be predicted from knowledge of mutagenicity and allergic contact dermatitis? Mut. Res. - Fund. Mol. M., 1999, 431 (1), 81-91.
30. Lewis, D.F.V.; Ioannides, C.; Parke, D.V. A combined COMPACT and HazardExpert study of 40 chemicals for which information on mutagenicity and carcinogenicity is known, including the results of human epidemiological studies Human Exper. Toxicol., 1998, 17 (10), 577-586.
31. Richard, A.M. Structure-based methods for predicting mutagenicity and carcinogenicity: Are we there yet? Mut. Res. - Fund. Mol. M., 1998, 400 (1-2), 493-507.
32. Klopman, G.; Rosenkranz, H.S. Approaches to SAR in carcinogenesis and mutagenesis. Prediction of carcinogenicity/mutagenicity using MULTI-CASE. Mut. Res. - Fund. Mol. M., 1994, 305 (1), 33-46.
33. Venitt, S.; Crofton-Sleigh, C.; Agbandje, M., Jenkins, T.C.; Neidle, S. Anthracene-9,10-diones as potential anticancer agents: Bacterial mutation studies of amido-substituted derivatives reveal an unexpected lack of mutagenicity. J. Med. Chem., 1998, 41(19), 3748-3752.
34. Juneja, T.R.; Bala, A.; Kumar, P.; Gupta, R.L. Mutagenicity of nitrobenzyl derivatives: Potential bioreductive anticancer agents. Mutat Res. Lett., 1995, 348 (3), 137-145.
35. The CORAL freeware (Correlation and Logic = CORAL), http://www.insilico.eu/CORAL (accessed January 9, 2012)
36. Concu, R.; Podda, G.; Ubeira, F.M.; González-Díaz, H. Review of QSAR models for Enzyme classes of drug targets: Theoretical background and applications in parasites, hosts and other organisms. Curr. Pharm. Des., 2010, 16 (24), 2710-2723.
37. Verma, J.; Khedkar, V.M.; Coutinho, E.C. 3D-QSAR in drug design - A review. Curr. Top. Med. Chem., 2010, 10 (1), 95-115.
38. Dudek, A.Z.; Arodz, T.; Gálvez, J. Computational methods in developing quantitative structure-activity relationships (QSAR): A review. Comb. Chem. High T. Scr., 2006, 9 (3), 213-228.
39. Jaworska, J.; Nikolova-Jeliazkova, N.; Aldenberg, T. QSAR applicability domain estimation by projection of the training set in descriptor space: A review. ATLA Altern. Lab. Anim., 2005, 33 (5), 445-459.
40. Karelson, M.; Maran, U.; Wang, Y.; Katritzky, A.R. QSPR and QSAR models derived using large molecular descriptor spaces. A review of CODESSA applications. Coll. Czechosl. Chem. Commun., 1999, 64 (1), 1551-1571.
41. Tuppurainen, K. Frontier orbital energies, hydrophobicity and steric factors as physical QSAR descriptors of molecular mutagenicity. A review with a case study: MX compounds. Chemosphere, 1999, 38 (13), 3015-3030.
42. Roy, K.; Mitra, I. On various metrics used for validation of predictive QSAR models with applications in virtual screening and focused library design. Comb. Chem. High T. Scr., 2011, 14 (6), 450-474.
43. Ojha, P.K.; Roy, K. Exploring QSAR, pharmacophore mapping and docking studies and virtual library generation for cycloguanil derivatives as PfDHFR-TS inhibitors. Med. Chem., 2011, 7 (3), pp. 173-199.
44. Hemmateenejad, B.; Yousefinejad, S.; Mehdipour, A.R. Novel amino acids indices based on quantum topological molecular similarity and their application to QSAR study of peptides. Amino Acids, 2011, 40 (4), pp. 1169-1183.
45. Hemmateenejad, B.; Mehdipour, A.R.; Miri, R., Shamsipur, M. Comparative qsar studies on toxicity of phenol derivatives using quantum topological molecular similarity indices. Chem. Biol. Drug Des., 2010, 75 (5), 521-531.
46. Melagraki, G., Afantitis, A. Ligand and structure based virtual screening strategies for hit-finding and optimization of Hepatitis C virus (HCV) inhibitors. Curr. Med. Chem., 2011, 18(17), 2612-2619.
47. Afantitis, A.; Melagraki, G.; Koutentis, P.A.; Sarimveis, H.; Kollias, G. Ligand - Based virtual screening procedure for the prediction and the identification of novel β-amyloid aggregation nhibitors using Kohonen maps and Counterpropagation Artificial Neural Networks. Eur. J. Med. Chem., 2011, 46 (2), 497-508.
48. Melagraki, G.; Afantitis, A.; Sarimveis, H.; Igglessi-Markopoulou, O.; Koutentis, P.A., Kollias, G. In silico exploration for identifying structure-activity relationship of MEK inhibition and oral bioavailability for isothiazole derivatives Chem. Biol. Drug Des., 2010, 76(5), 397-406.
49. Toropov, A.A.; Toropova, A.P.; Benfenati, E.; Gini, G.; Leszczynska, D.; Leszczynski, J. SMILES-based QSAR approaches for carcinogenicity and anticancer activity: Comparison of correlation weights for identical SMILES attributes. Anti-cancer. Agents. Med. Chem., 2011, 11(10), 974-982.
50. Atanasova, M.; Ilieva, S.; Galabov, B. QSAR analysis of 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridines with anticancer activity Eur. J. Med. Chem., 2007, 42 (9), 1184-1192.
51. Cash, G.G. Prediction of the genotoxicity of aromatic and heteroaromatic amines using electrotopological state indices Mutat. Res., 2001, 491 (1-2), 31-37.
52. Ojha, P.K.; Mitra, I.; Das, R.N.; Kunal Roy, K. Further exploring rm 2 metrics for validation of QSPR models Chemometr. Intell. Lab., 2011, 107(1), 194-205.
53. Toropov, A.A.; Toropova, A.P.; Benfenati, E. QSAR modelling of the toxicity to Tetrahymena pyriformis by balance of correlations Mol. Divers., 2010, 14(4), 821-827.
54. Toropov, A.A.; Toropova, A.P.; Benfenati, E.; Leszczynska, D.; Leszczynski, J. SMILES-Based Optimal Descriptors: QSAR Analysis of Fullerene-Based HIV-1 PR Inhibitors by Means of Balance of Correlations. J. Comput. Chem., 2010, 31(2), 381-392.
55. Toropov, A.A.; Toropova, A.P.; Benfenati, E.; Leszczynska, D.; Leszczynski, J. InChI-based optimal descriptors: QSAR analysis of fullerene[C60]-based HIV-1 PR inhibitors by correlation balance. Eur. J. Med. Chem., 2010, 45(4), 1387-1394.
56. Toropov, A. A.; Toropova, A.P.; Raska, I.; Benfenati, E. QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations. Eur. J. Med. Chem. 2010, 45 (5), 1639-1647.
57. Toropov, A.A.; Toropova, A.P.; Benfenati, E. QSAR-modeling of toxicity of organometallic compounds by means of the balance of correlations for InChI-based optimal descriptors. Mol. Divers., 2010, 14 (1), 183-192.
58. Toropov, A.A.; Toropova, A.P.; Benfenati, E.; Manganaro, A. QSAR modelling of carcinogenicity by balance of correlations. Mol. Divers., 2009, 13(3), 367-373.
59. Toropov, A.A.; Toropova, A.P.; Benfenati, E. QSPR modeling bioconcentration factor (BCF) by balance of correlations. Eur. J. Med. Chem., 2009, 44 (6), 2544-2551.
60. Toropov, A.A.; Rasulev, B.F.; Leszczynski, J. QSAR modeling of acute toxicity by balance of correlations. Bioorg. Med. Chem., 2008, 16(11), 5999-6008.
61. Toropova, A.P.; Toropov, A.A.; Benfenati, E.; Gini, G.; Leszczynska, D.; Leszczynski, J. QSAR modeling of anxiolytic activity taking into account the presence of keto- and enoltautomers by balance of correlations with ideal slopes. Cent. Eur. J. Chem., 2011, 9(5), 846-854.